



Division: Pharmacy Policy	Subject: Prior Authorization Criteria
Original Development Date: Original Effective Date: Revision Date:	May 10, 2024

Ycanth™ (cantharidin)

LENGTH OF AUTHORIZATION: 12 weeks

REVIEW CRITERIA:

- Patient must be ≥ 2 years of age.
- Patient must have a documented diagnosis of molluscum contagiosum.
- Medication will be applied by a trained healthcare provider to treat molluscum contagiosum lesions.
- Medication was prescribed by or in consultation with a dermatologist.
- One of the following must be true:
 - Patient has molluscum contagiosum lesions that were not previously treated with Ycanth™; **OR**
 - Patient has molluscum contagiosum lesions that were previously treated with Ycanth™ and has **not** exceed a total of 4 treatments.

***Note:** Ycanth™ is flammable. Patients should be advised to avoid fire, flames, or smoking near lesion(s) during treatment and after application until the medication is removed.*

DOSING AND ADMINISTRATION:

- Refer to product labeling at <https://www.accessdata.fda.gov/scripts/cder/daf/>
- Available as 0.7% topical solution.